Temporal trends and patterns in carbamazepine use, related severe cutaneous adverse reactions, and <scp>HLA</scp>‐B*15:02 screening: A nationwide study

Abstract

In recent years, the number of carbamazepine-related SCAR cases has decreased substantially in Taiwan. However, only one-fourth of new users of carbamazepine received HLA-B*15:02 screening, and there were considerable disparities in the screening rates across different physician groups. Policymakers should consider solutions to barriers to implementing screening tests in clinical practice and should not neglect the value of other safety communications and regulations to complement the limitations of pharmacogenomic testing.